Over the last 7 days, the Biotech industry has risen 6.5%, driven by gains from Innovent Biologics of 4.1%. In the same time, ImmuneOnco Biopharmaceuticals (Shanghai) was down 17%. In contrast, the industry has lost 26% in the last 12 months. As for the next few years, earnings are expected to grow by 34% per annum.
Has the Hong Kong Biotech Industry valuation changed over the past few years?
Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
---|---|---|---|---|---|---|
Thu, 08 Aug 2024 | HK$328.8b | HK$50.3b | -HK$19,745,832,215.85 | 11.5x | -16.7x | 6.5x |
Sat, 06 Jul 2024 | HK$330.3b | HK$49.7b | -HK$19,449,392,369.45 | 12.3x | -17x | 6.7x |
Mon, 03 Jun 2024 | HK$340.5b | HK$49.8b | -HK$19,538,408,792.63 | 12x | -17.4x | 6.8x |
Wed, 01 May 2024 | HK$358.9b | HK$49.8b | -HK$19,215,749,614.00 | 12x | -18.7x | 7.2x |
Fri, 29 Mar 2024 | HK$341.5b | HK$49.3b | -HK$19,213,003,345.42 | 13.7x | -17.8x | 6.9x |
Sun, 25 Feb 2024 | HK$340.7b | HK$47.2b | -HK$20,399,038,636.02 | 15.6x | -16.7x | 7.2x |
Tue, 23 Jan 2024 | HK$322.7b | HK$46.7b | -HK$20,165,286,417.00 | 15.9x | -16x | 6.9x |
Thu, 21 Dec 2023 | HK$390.8b | HK$47.0b | -HK$20,285,175,535.00 | 17x | -19.3x | 8.3x |
Sat, 18 Nov 2023 | HK$410.5b | HK$46.0b | -HK$18,531,488,253.00 | 18.8x | -22.2x | 8.9x |
Mon, 16 Oct 2023 | HK$400.9b | HK$44.9b | -HK$19,108,661,851.00 | 14.7x | -21x | 8.9x |
Wed, 13 Sep 2023 | HK$412.4b | HK$45.0b | -HK$18,959,678,090.00 | 15.5x | -21.8x | 9.2x |
Fri, 11 Aug 2023 | HK$385.3b | HK$35.4b | -HK$23,295,317,599.00 | 22.4x | -16.5x | 10.9x |
Sun, 09 Jul 2023 | HK$397.9b | HK$35.4b | -HK$23,251,738,893.00 | 24.6x | -17.1x | 11.2x |
Tue, 06 Jun 2023 | HK$407.0b | HK$35.8b | -HK$23,607,031,243.00 | 27x | -17.2x | 11.4x |
Thu, 04 May 2023 | HK$436.0b | HK$36.7b | -HK$23,527,703,886.00 | 17.8x | -18.5x | 11.9x |
Sat, 01 Apr 2023 | HK$433.3b | HK$36.0b | -HK$26,221,924,146.00 | 12.2x | -16.5x | 12x |
Mon, 27 Feb 2023 | HK$403.3b | HK$34.3b | -HK$34,519,333,916.00 | 31.2x | -11.7x | 11.8x |
Wed, 25 Jan 2023 | HK$452.0b | HK$34.9b | -HK$35,254,683,930.00 | 29.8x | -12.8x | 13x |
Fri, 23 Dec 2022 | HK$379.3b | HK$33.6b | -HK$33,888,461,212.00 | 23.6x | -11.2x | 11.3x |
Sun, 20 Nov 2022 | HK$379.9b | HK$33.1b | -HK$33,398,435,151.00 | 16.7x | -11.4x | 11.5x |
Tue, 18 Oct 2022 | HK$297.6b | HK$33.7b | -HK$32,213,028,064.00 | 15.5x | -9.2x | 8.8x |
Thu, 15 Sep 2022 | HK$325.5b | HK$34.5b | -HK$33,771,354,759.00 | 16.5x | -9.6x | 9.4x |
Sat, 13 Aug 2022 | HK$337.1b | HK$32.8b | -HK$46,358,308,284.00 | 12.2x | -7.3x | 10.3x |
Mon, 11 Jul 2022 | HK$375.7b | HK$33.1b | -HK$46,688,664,217.00 | 14.4x | -8x | 11.4x |
Wed, 08 Jun 2022 | HK$339.6b | HK$34.3b | -HK$46,230,730,016.00 | 13.5x | -7.3x | 9.9x |
Fri, 06 May 2022 | HK$324.6b | HK$34.4b | -HK$45,770,185,245.00 | 12.9x | -7.1x | 9.4x |
Sun, 03 Apr 2022 | HK$349.4b | HK$36.4b | -HK$45,994,151,540.00 | 16.6x | -7.6x | 9.6x |
Tue, 01 Mar 2022 | HK$339.3b | HK$34.0b | -HK$31,189,039,484.00 | 12.8x | -10.9x | 10x |
Thu, 27 Jan 2022 | HK$320.2b | HK$31.2b | -HK$31,971,453,352.00 | 11.9x | -10x | 10.3x |
Sat, 25 Dec 2021 | HK$403.2b | HK$31.1b | -HK$31,826,324,087.00 | 13.2x | -12.7x | 13x |
Mon, 22 Nov 2021 | HK$519.0b | HK$31.0b | -HK$31,710,521,061.00 | 13.6x | -16.4x | 16.7x |
Wed, 20 Oct 2021 | HK$509.0b | HK$30.6b | -HK$31,591,228,157.00 | 14.9x | -16.1x | 16.7x |
Fri, 17 Sep 2021 | HK$500.7b | HK$30.5b | -HK$32,407,587,825.00 | 16.3x | -15.5x | 16.4x |
Sun, 15 Aug 2021 | HK$545.4b | HK$30.2b | -HK$32,058,827,347.35 | 15.3x | -17x | 18x |
-17x
Which industries have driven the changes within the Hong Kong Healthcare industry?
HK Market | -1.71% | |
Healthcare | 4.99% | |
Biotech | 6.48% | |
Biotech | 6.48% |
Which companies have driven the market over the last 7 days?
Company | Last Price | 7D | 1Y | Valuation | |
---|---|---|---|---|---|
1801 Innovent Biologics | HK$40.30 | 4.1% +HK$2.6b | 25.2% | PS9.7x | |
9926 Akeso | HK$44.55 | 5.3% +HK$1.9b | 29.3% | PE17.5x | |
2162 Keymed Biosciences | HK$34.20 | 8.7% +HK$760.7m | -30.1% | PS24.6x | |
2511 HighTide Therapeutics | HK$1.86 | 64.6% +HK$375.8m | n/a | PB1.3x | |
2696 Shanghai Henlius Biotech | HK$22.95 | 2.7% +HK$326.1m | 100.6% | PE21x |